[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100514245":3},{"organization":4,"armGroups":7,"interventions":20,"overallOfficials":25,"centralContacts":28,"locations":36,"responsibleParty":154,"collaborators":25,"id":156,"slug":25,"hasResults":157,"nctId":158,"briefTitle":159,"officialTitle":160,"acronym":25,"eligibilityCriteria":161,"healthyVolunteers":157,"sex":162,"minAge":163,"maxAge":25,"enrollmentInfo":164,"targetDuration":25,"studyType":167,"phases":168,"briefSummary":170,"conditions":171,"keywords":173,"overallStatus":39,"whyStopped":25,"lastUpdateSubmitDate":181,"lastUpdatePostDateStruct":182,"startDateStruct":185,"completionDateStruct":187,"leadSponsor":189,"locationsCount":190},{"fullName":5,"class":6},"InSilico Medicine Hong Kong Limited","INDUSTRY",[8,14],{"label":9,"type":10,"description":11,"interventionNames":12},"INS018_055","EXPERIMENTAL","INS018\\_055 is administered once daily up to 12 weeks",[13],"Drug: INS018_055",{"label":15,"type":16,"description":17,"interventionNames":18},"Placebo","PLACEBO_COMPARATOR","Placebo is administered once daily up to 12 weeks",[19],"Drug: Placebo",[21,26],{"type":22,"name":9,"description":23,"armGroupLabels":24,"otherNames":25},"DRUG","Pharmaceutical formulation: Tablet\n\nMode of Administration: Oral",[9],null,{"type":22,"name":15,"description":23,"armGroupLabels":27,"otherNames":25},[15],[29,34],{"name":30,"role":31,"phone":32,"phoneExt":25,"email":33},"Monique Duncan","CONTACT","+86 18817554306","Insilico-Clinicaltrial@insilico.ai",{"name":35,"role":31,"phone":25,"phoneExt":25,"email":33},"Carol Salter, MD, PhD",[37,50,60,70,80,89,99,109,119,129,139,148],{"facility":38,"status":39,"city":40,"state":41,"zip":42,"country":43,"cosmosGeoPoint":44,"geoPoint":49,"contacts":25},"University of Alabama at Birmingham","RECRUITING","Birmingham","Alabama","35294","United States",{"type":45,"coordinates":46},"Point",[47,48],-86.80249,33.52066,{"lat":48,"lon":47},{"facility":51,"status":39,"city":52,"state":53,"zip":54,"country":43,"cosmosGeoPoint":55,"geoPoint":59,"contacts":25},"HonorHealth Research Institute","Scottsdale","Arizona","85258",{"type":45,"coordinates":56},[57,58],-111.89903,33.50921,{"lat":58,"lon":57},{"facility":61,"status":39,"city":62,"state":63,"zip":64,"country":43,"cosmosGeoPoint":65,"geoPoint":69,"contacts":25},"Keck School of Medicine of USC","Los Angeles","California","90033",{"type":45,"coordinates":66},[67,68],-118.24368,34.05223,{"lat":68,"lon":67},{"facility":71,"status":39,"city":72,"state":73,"zip":74,"country":43,"cosmosGeoPoint":75,"geoPoint":79,"contacts":25},"Florida Lung Asthma and Sleep Specialist","Celebration","Florida","34747-1818",{"type":45,"coordinates":76},[77,78],-81.53313,28.32529,{"lat":78,"lon":77},{"facility":81,"status":39,"city":82,"state":73,"zip":83,"country":43,"cosmosGeoPoint":84,"geoPoint":88,"contacts":25},"Central Florida Pulmonary Group, P.A. (CFPG) - Downtown Orlando","Orlando","32803-5727",{"type":45,"coordinates":85},[86,87],-81.37924,28.53834,{"lat":87,"lon":86},{"facility":90,"status":39,"city":91,"state":92,"zip":93,"country":43,"cosmosGeoPoint":94,"geoPoint":98,"contacts":25},"Southeastern Research Center","Winston-Salem","North Carolina","27103-4007",{"type":45,"coordinates":95},[96,97],-80.24422,36.09986,{"lat":97,"lon":96},{"facility":100,"status":39,"city":101,"state":102,"zip":103,"country":43,"cosmosGeoPoint":104,"geoPoint":108,"contacts":25},"University of Oklahoma Health Sciences Center (OUHSC)","Oklahoma City","Oklahoma","73104-5417",{"type":45,"coordinates":105},[106,107],-97.51643,35.46756,{"lat":107,"lon":106},{"facility":110,"status":39,"city":111,"state":112,"zip":113,"country":43,"cosmosGeoPoint":114,"geoPoint":118,"contacts":25},"Temple University Hospital-Temple Lung Center","Philadelphia","Pennsylvania","19140",{"type":45,"coordinates":115},[116,117],-75.16362,39.95238,{"lat":117,"lon":116},{"facility":120,"status":39,"city":121,"state":122,"zip":123,"country":43,"cosmosGeoPoint":124,"geoPoint":128,"contacts":25},"Bogan Sleep Consultants, LLC","Columbia","South Carolina","29201-2953",{"type":45,"coordinates":125},[126,127],-81.03481,34.00071,{"lat":127,"lon":126},{"facility":130,"status":39,"city":131,"state":132,"zip":133,"country":43,"cosmosGeoPoint":134,"geoPoint":138,"contacts":25},"University of Texas Southwestern Medical Center","Dallas","Texas","75235-6243",{"type":45,"coordinates":135},[136,137],-96.80667,32.78306,{"lat":137,"lon":136},{"facility":140,"status":39,"city":141,"state":132,"zip":142,"country":43,"cosmosGeoPoint":143,"geoPoint":147,"contacts":25},"Metroplex Pulmonary and Sleep Center","McKinney","75069-1898",{"type":45,"coordinates":144},[145,146],-96.61527,33.19762,{"lat":146,"lon":145},{"facility":149,"status":39,"city":141,"state":132,"zip":150,"country":43,"cosmosGeoPoint":151,"geoPoint":153,"contacts":25},"Research Centers of America","75071",{"type":45,"coordinates":152},[145,146],{"lat":146,"lon":145},{"type":155,"investigatorFullName":25,"investigatorTitle":25,"investigatorAffiliation":25,"oldNameTitle":25,"oldOrganization":25},"SPONSOR","100514245",false,"NCT05975983","Study Evaluating INS018_055 Administered Orally to Subjects With Idiopathic Pulmonary Fibrosis","A Phase IIa, Randomized, Double-Blind, Placebo-Controlled Study Evaluating the Safety, Tolerability, Pharmacokinetics, and Efficacy of INS018_055 Administered Orally to Subjects With Idiopathic Pulmonary Fibrosis (IPF)","Inclusion Criteria:\n\n1. Male or female patients aged ≥40 years based on the date of the written informed consent form\n2. Diagnosis of IPF as defined by American Thoracic Society\u002FEuropean Respiratory Society\u002FJapanese Respiratory Society\u002FLatin American Thoracic Association guidelines\n3. In a stable condition and suitable for study participation based on the results of medical history, physical examination, vital signs, 12-lead ECG, and laboratory evaluation\n4. Meeting all of the following criteria during the screening period:\n\n   1. FVC ≥40% predicted normal\n   2. DLCO corrected for Hgb ≥25% and \\\u003C80% predicted normal\n   3. Forced Expiratory Volume in the first second\u002FFVC (FEV1\u002FFVC) ratio \\>0.7 based on pre-bronchodilator value\n\nExclusion Criteria:\n\n1. Acute IPF exacerbation within 4 months prior to Visit 1 and\u002For Day 1, as determined by the investigator\n2. Patients who are unwilling to refrain from smoking within 3 months prior to screening and until the end of the study\n3. Female patients who are pregnant or nursing\n4. Abnormal ECG findings","ALL","40 Years",{"count":165,"type":166},40,"ESTIMATED","INTERVENTIONAL",[169],"PHASE2","The purpose of this revised Phase IIa study is to demonstrate safety of INS018\\_055 over 12 weeks in adults with Idiopathic Pulmonary Fibrosis (IPF).",[172],"Idiopathic Pulmonary Fibrosis (IPF)",[174,175,176,177,178,179,180],"Pulmonary Fibrosis","Idiopathic Pulmonary Fibrosis","Fibrosis","Pathologic Processes","Lung Diseases, Interstitial","Lung Diseases","Respiratory Tract Diseases","2025-11-10",{"date":183,"type":184},"2025-11-12","ACTUAL",{"date":186,"type":184},"2024-02-08",{"date":188,"type":166},"2026-02-28",{"name":5,"class":6},12]